Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 389

1.

Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.

Janssen PM, Murray JD, Schill KE, Rastogi N, Schultz EJ, Tran T, Raman SV, Rafael-Fortney JA.

PLoS One. 2014 Feb 13;9(2):e88360. doi: 10.1371/journal.pone.0088360.

2.

Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice.

Rafael-Fortney JA, Chimanji NS, Schill KE, Martin CD, Murray JD, Ganguly R, Stangland JE, Tran T, Xu Y, Canan BD, Mays TA, Delfín DA, Janssen PM, Raman SV.

Circulation. 2011 Aug 2;124(5):582-8. doi: 10.1161/CIRCULATIONAHA.111.031716.

3.

Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.

Gutpell KM, Hrinivich WT, Hoffman LM.

PLoS One. 2015 Jan 21;10(1):e0117306. doi: 10.1371/journal.pone.0117306.

4.

Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice.

Spurney CF, Sali A, Guerron AD, Iantorno M, Yu Q, Gordish-Dressman H, Rayavarapu S, van der Meulen J, Hoffman EP, Nagaraju K.

J Cardiovasc Pharmacol Ther. 2011 Mar;16(1):87-95. doi: 10.1177/1074248410381757.

5.

Improvement of cardiac contractile function by peptide-based inhibition of NF-κB in the utrophin/dystrophin-deficient murine model of muscular dystrophy.

Delfín DA, Xu Y, Peterson JM, Guttridge DC, Rafael-Fortney JA, Janssen PM.

J Transl Med. 2011 May 17;9:68. doi: 10.1186/1479-5876-9-68.

6.

Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.

Church JE, Trieu J, Chee A, Naim T, Gehrig SM, Lamon S, Angelini C, Russell AP, Lynch GS.

Exp Physiol. 2014 Apr;99(4):675-87. doi: 10.1113/expphysiol.2013.077255.

7.

Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice.

van Putten M, Hulsker M, Young C, Nadarajah VD, Heemskerk H, van der Weerd L, 't Hoen PA, van Ommen GJ, Aartsma-Rus AM.

FASEB J. 2013 Jun;27(6):2484-95. doi: 10.1096/fj.12-224170.

8.

Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains.

van Putten M, Kumar D, Hulsker M, Hoogaars WM, Plomp JJ, van Opstal A, van Iterson M, Admiraal P, van Ommen GJ, 't Hoen PA, Aartsma-Rus A.

Neuromuscul Disord. 2012 May;22(5):406-17. doi: 10.1016/j.nmd.2011.10.011.

9.

Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.

Percival JM, Whitehead NP, Adams ME, Adamo CM, Beavo JA, Froehner SC.

J Pathol. 2012 Sep;228(1):77-87. doi: 10.1002/path.4054.

10.

Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice.

Ebihara S, Guibinga GH, Gilbert R, Nalbantoglu J, Massie B, Karpati G, Petrof BJ.

Physiol Genomics. 2000 Sep 8;3(3):133-44.

PMID:
11015608
11.

The proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx mice.

Sali A, Many GM, Gordish-Dressman H, van der Meulen JH, Phadke A, Spurney CF, Cnaan A, Hoffman EP, Nagaraju K.

PLoS One. 2013 Jul 2;8(7):e66617. doi: 10.1371/journal.pone.0066617.

12.

Weekly oral prednisolone improves survival and strength in male mdx mice.

Keeling RM, Golumbek PT, Streif EM, Connolly AM.

Muscle Nerve. 2007 Jan;35(1):43-8.

PMID:
16969833
13.

Diaphragm rescue alone prevents heart dysfunction in dystrophic mice.

Crisp A, Yin H, Goyenvalle A, Betts C, Moulton HM, Seow Y, Babbs A, Merritt T, Saleh AF, Gait MJ, Stuckey DJ, Clarke K, Davies KE, Wood MJ.

Hum Mol Genet. 2011 Feb 1;20(3):413-21. doi: 10.1093/hmg/ddq477.

14.

Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for duchenne muscular dystrophy.

Chun JL, O'Brien R, Song MH, Wondrasch BF, Berry SE.

Stem Cells Transl Med. 2013 Jan;2(1):68-80. doi: 10.5966/sctm.2012-0107. Erratum in: Stem Cells Transl Med. 2013 Feb;2(2):following 158.

15.

Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy.

Bauer R, Straub V, Blain A, Bushby K, MacGowan GA.

Eur J Heart Fail. 2009 May;11(5):463-71. doi: 10.1093/eurjhf/hfp028.

16.

Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice.

Bish LT, Yarchoan M, Sleeper MM, Gazzara JA, Morine KJ, Acosta P, Barton ER, Sweeney HL.

PLoS One. 2011;6(6):e20856. doi: 10.1371/journal.pone.0020856.

17.

Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice.

Zhou L, Rafael-Fortney JA, Huang P, Zhao XS, Cheng G, Zhou X, Kaminski HJ, Liu L, Ransohoff RM.

J Neurol Sci. 2008 Jan 15;264(1-2):106-11.

18.

Dystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10.

Nitahara-Kasahara Y, Hayashita-Kinoh H, Chiyo T, Nishiyama A, Okada H, Takeda S, Okada T.

Hum Mol Genet. 2014 Aug 1;23(15):3990-4000. doi: 10.1093/hmg/ddu113.

19.

The role of proteases in excitation-contraction coupling failure in muscular dystrophy.

Mázala DA, Grange RW, Chin ER.

Am J Physiol Cell Physiol. 2015 Jan 1;308(1):C33-40. doi: 10.1152/ajpcell.00267.2013.

20.
Items per page

Supplemental Content

Support Center